|Nerve growth factor promotes cardiac repair following myocardial infarction.|
|PMID: 20360245 Owner: NLM Status: MEDLINE|
|RATIONALE: Nerve growth factor (NGF) promotes angiogenesis and cardiomyocyte survival, which are both desirable for postinfarction myocardial healing. Nonetheless, the NGF potential for cardiac repair has never been investigated.
OBJECTIVE: To define expression and localization of NGF and its high-affinity receptor TrkA (tropomyosin-related receptor A) in the human infarcted heart and to investigate the cardiac roles of both endogenous and engineered NGF using a mouse model of myocardial infarction (MI).
METHODS AND RESULTS: Immunostaining for NGF and TrkA was performed on heart samples from humans deceased of MI or unrelated pathologies. To study the post-MI functions of endogenous NGF, a NGF-neutralizing antibody (Ab-NGF) or nonimmune IgG (control) was given to MI mice. To investigate the NGF therapeutic potential, human NGF gene or control (empty vector) was delivered to the murine periinfarct myocardium. Results indicate that NGF is present in the infarcted human heart. Both cardiomyocytes and endothelial cells (ECs) possess TrkA, which suggests NGF cardiovascular actions in humans. In MI mice, Ab-NGF abrogated native reparative angiogenesis, increased EC and cardiomyocyte apoptosis and worsened cardiac function. Conversely, NGF gene transfer ameliorated EC and cardiomyocyte survival, promoted neovascularization and improved myocardial blood flow and cardiac function. The prosurvival/proangiogenic Akt/Foxo pathway mediated the therapeutic benefits of NGF transfer. Moreover, NGF overexpression increased stem cell factor (the c-kit receptor ligand) expression, which translated in higher myocardial abundance of c-kit(pos) progenitor cells in NGF-engineered hearts.
CONCLUSIONS: NGF elicits pleiotropic beneficial actions in the post-MI heart. NGF should be considered as a candidate for therapeutic cardiac regeneration.
|Marco Meloni; Andrea Caporali; Gallia Graiani; Costanza Lagrasta; Rajesh Katare; Sophie Van Linthout; Frank Spillmann; Ilaria Campesi; Paolo Madeddu; Federico Quaini; Costanza Emanueli|
Related Documents :
|17893005 - Multiple-polymorphism associations of 7 matrix metalloproteinase and tissue inhibitor m...
16236935 - Reduced ejection fraction after myocardial infarction: is it sufficient to justify impl...
23727105 - Prehospital ecg signs of acute coronary occlusion are associated with reduced one-year ...
23741055 - Putting the "vascular" back into cardiovascular research: st-elevation myocardial infar...
17874985 - Tako-tsubo cardiomyopathy: how stress can mimic acute coronary occlusion.
2147705 - Origin and significance of diastolic doppler flow signals in the left ventricular outfl...
|Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2010-04-01|
|Title: Circulation research Volume: 106 ISSN: 1524-4571 ISO Abbreviation: Circ. Res. Publication Date: 2010 Apr|
|Created Date: 2010-04-16 Completed Date: 2010-04-30 Revised Date: 2013-05-29|
Medline Journal Info:
|Nlm Unique ID: 0047103 Medline TA: Circ Res Country: United States|
|Languages: eng Pagination: 1275-84 Citation Subset: IM|
|Experimental Cardiovascular Medicine Division, Bristol Heart Institute, Bristol, United Kingdom.|
|APA/MLA Format Download EndNote Download BibTex|
Disease Models, Animal
Endothelial Cells / metabolism*, pathology
Forkhead Transcription Factors / metabolism
Myocardial Infarction / genetics, metabolism, pathology, physiopathology, therapy*
Myocardium / metabolism*, pathology
Nerve Growth Factor / biosynthesis*, genetics
Proto-Oncogene Proteins c-akt / metabolism
Proto-Oncogene Proteins c-kit / metabolism
RNA, Messenger / biosynthesis
Receptor, trkA / metabolism
Recombinant Proteins / biosynthesis
Regeneration* / genetics
Stem Cell Factor / metabolism
Stem Cells / metabolism, pathology
Ventricular Function, Left
|BS/05/001//British Heart Foundation; BS/05/001/18360//British Heart Foundation; PG/06/146/21946//British Heart Foundation; PG/06/146/21946//British Heart Foundation|
|0/Forkhead Transcription Factors; 0/FoxO3 protein, mouse; 0/NGF protein, human; 0/RNA, Messenger; 0/Recombinant Proteins; 0/Stem Cell Factor; 9061-61-4/Nerve Growth Factor; EC 220.127.116.11/Proto-Oncogene Proteins c-kit; EC 18.104.22.168/Receptor, trkA; EC 22.214.171.124/Proto-Oncogene Proteins c-akt|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Community Incidence of Norovirus-associated Infectious Intestinal Disease in England: Improved Estim...
Next Document: Pregnenolone sulphate- and cholesterol-regulated TRPM3 channels coupled to vascular smooth muscle se...